The value of economic modeling studies in the evaluation of treatment strategies for multiple sclerosis

Value in Health

Volumn 5, Issue 1, 2002, Pages 1-2

  Detournay, Bruno ^a  

^a CEMKA EVAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; GLATIRAMER;

COST OF ILLNESS; ECONOMIC ASPECT; EDITORIAL; HUMAN; MULTIPLE SCLEROSIS; OUTCOMES RESEARCH; PREVALENCE; PRIORITY JOURNAL;

EID: 0036168463     PISSN: 10983015     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1524-4733.2002.51001.x     Document Type: Editorial

References (11)

1. Multiple sclerosis
2. A purchaser perspective of managing new drugs: Interferon beta as a case study
3. Recommendations from the national multiple sclerosis society clinical outcomes assessment task force
4. Drug treatment of multiple sclerosis. Clinical review was unsystematic
5. Economic evaluation of multiple sclerosis in the UK, Germany and France
6. Burden of illness of multiple sclerosis part 1: Cost of illness
7. The economic cost of MS in Sweden in 1994
8. Cost-utility analysis of interferon beta-1b in secondary progressive multiple sclerosis
9. Long-term treatment of multiple sclerosis with interferon-beta may be cost effective
10. Inter- and intrarater scoring agreement using grades 1.0-3.5 of the Kurtzke Expanded Disability Status Scale (EDSS): Multiple Sclerosis Collaborative Research Group